Pingji Liu
Overview
Explore the profile of Pingji Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiong Z, Chen P, Wang Z, Yao L, Yuan M, Liu P, et al.
Free Radic Biol Med
. 2025 Mar;
231:163-177.
PMID: 40023296
Liver fibrosis is a reversible dynamic pathological process induced by chronic liver injury. Without intervention, liver fibrosis can progress to become cirrhosis, liver failure, or hepatocellular carcinoma, thus posing a...
2.
Yuan M, Hu X, Yao L, Chen P, Wang Z, Liu P, et al.
J Clin Transl Hepatol
. 2024 Feb;
12(2):123-133.
PMID: 38343609
Background And Aims: Accumulating evidence highlights the association between the gut microbiota and liver cirrhosis. However, the role of the gut microbiota in liver cirrhosis remains unclear. Methods: We first...
3.
Xiong Z, Chen P, Yuan M, Yao L, Wang Z, Liu P, et al.
Biomolecules
. 2024 Jan;
14(1).
PMID: 38275754
Liver cirrhosis remains a significant global public health concern, with liver transplantation standing as the foremost effective treatment currently available. Therefore, investigating the pathogenesis of liver cirrhosis and developing novel...
4.
Chen P, Yuan M, Yao L, Xiong Z, Liu P, Wang Z, et al.
Biomed Pharmacother
. 2024 Jan;
171:116133.
PMID: 38198960
Chronic Liver fibrosis may progress to liver cirrhosis and hepatocellular carcinoma (HCC), hence cause a substantial global burden. However, effective therapies for blocking fibrosis are still lacking. Although mesenchymal stem...
5.
Yuan M, Yao L, Chen P, Wang Z, Liu P, Xiong Z, et al.
Int Immunopharmacol
. 2023 Nov;
125(Pt A):111134.
PMID: 37918086
Background: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have garnered considerable attention as prospective modalities of treatment for liver fibrosis (LF). The inhibition of hepatic stellate cell (HSC) activation underlies...
6.
Wang Z, Yao L, Hu X, Yuan M, Chen P, Liu P, et al.
Tissue Cell
. 2023 Aug;
84:102198.
PMID: 37604091
Chronic liver disease inevitably progresses to liver cirrhosis, significantly compromising patients' overall survival and quality of life. However, a glimmer of hope emerges with the emergence of mesenchymal stem cells,...
7.
Yao L, Hu X, Yuan M, Liu P, Zhang Q, Wang Z, et al.
Int Immunopharmacol
. 2023 Jul;
123:110456.
PMID: 37494836
Background: Few effective anti-fibrotic therapies are currently available for liver cirrhosis. Mesenchymal stromal cells (MSCs) ameliorate liver fibrosis and contribute to liver regeneration after cirrhosis, attracting much attention as a...
8.
Hypertension and NAFLD risk: Insights from the NHANES 2017-2018 and Mendelian randomization analyses
Yuan M, He J, Hu X, Yao L, Chen P, Wang Z, et al.
Chin Med J (Engl)
. 2023 Jul;
137(4):457-464.
PMID: 37455323
Background: Hypertension and non-alcoholic fatty liver disease (NAFLD) share several pathophysiologic risk factors, and the exact relationship between the two remains unclear. Our study aims to provide evidence concerning the...
9.
Yao L, Hu X, Yuan M, Zhang Q, Liu P, Yang L, et al.
J Clin Transl Hepatol
. 2023 Jul;
11(4):787-799.
PMID: 37408817
Background And Aims: Liver cirrhosis can lead to liver failure and eventually death. Macrophages are the main contributors to cirrhosis and have a bidirectional role in regulating matrix deposition and...
10.
Recent advances in the immunomodulation mechanism of mesenchymal stem cell therapy in liver diseases
Liu P, Yao L, Hu X, Wang Z, Xiong Z, Jiang Y
J Gastroenterol Hepatol
. 2023 Jun;
38(7):1099-1106.
PMID: 37271943
Liver fibrosis, acute liver injury or liver failure, liver tumors, and immune rejection after liver transplantation are common clinical liver diseases. Immune responses are the key to determining the prognosis...